A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Genmab
BriaCell Therapeutics Corporation
Eli Lilly and Company
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Essen Biotech
National Institutes of Health Clinical Center (CC)
Gustave Roussy, Cancer Campus, Grand Paris
University of Ulm
University Health Network, Toronto
Vastra Gotaland Region
National Hospital Organization Nagoya Medical Center